Faeth Therapeutics (FTH) Operating Leases (2022 - 2025)

Faeth Therapeutics (FTH) has reported Operating Leases for 4 consecutive years, with $59000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 95.87% year-over-year to $59000.0; the trailing twelve-month figure through Dec 2025 stood at $59000.0 (down 95.87% YoY), and the FY2025 full-year result was $59000.0, down 95.87% from the prior year.
• Operating Leases retreated to $59000.0 in Q4 2025 per FTH's latest filing, from $146000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $5.3 million in Q1 2022 and bottomed at $59000.0 in Q4 2025.
• Historically, Operating Leases has averaged $2.7 million across 4 years, with a median of $2.8 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases fell 21.96% in 2023, then slumped 95.87% in 2025.
• Over 4 years, Operating Leases stood at $4.3 million in 2022, then plunged by 30.58% to $3.0 million in 2023, then plunged by 52.38% to $1.4 million in 2024, then plunged by 95.87% to $59000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $59000.0, $146000.0, and $592000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.